MX353299B - Metodos y composiciones relacionadas con p62 para el tratamiento y profilaxis del cancer. - Google Patents

Metodos y composiciones relacionadas con p62 para el tratamiento y profilaxis del cancer.

Info

Publication number
MX353299B
MX353299B MX2014001418A MX2014001418A MX353299B MX 353299 B MX353299 B MX 353299B MX 2014001418 A MX2014001418 A MX 2014001418A MX 2014001418 A MX2014001418 A MX 2014001418A MX 353299 B MX353299 B MX 353299B
Authority
MX
Mexico
Prior art keywords
cancer
prophylaxis
treatment
methods
compositions relating
Prior art date
Application number
MX2014001418A
Other languages
English (en)
Other versions
MX2014001418A (es
Inventor
Shneider Alexander
Venanzi Franco
Sherman Michael
Shifrin Victor
Original Assignee
Curelab Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curelab Oncology Inc filed Critical Curelab Oncology Inc
Publication of MX2014001418A publication Critical patent/MX2014001418A/es
Publication of MX353299B publication Critical patent/MX353299B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a novedosas composiciones de p62 para la profilaxis y el tratamiento del cáncer y métodos relacionados. La invención también proporciona composiciones de p62 modificado que aumentan la actividad anticancerígena de p62.
MX2014001418A 2011-08-08 2012-08-08 Metodos y composiciones relacionadas con p62 para el tratamiento y profilaxis del cancer. MX353299B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161521280P 2011-08-08 2011-08-08
RU2012108927 2012-03-11
PCT/US2012/050024 WO2013022991A2 (en) 2011-08-08 2012-08-08 Methods and compositions relating to p62 for the treatment and prophylaxis of cancer

Publications (2)

Publication Number Publication Date
MX2014001418A MX2014001418A (es) 2014-09-15
MX353299B true MX353299B (es) 2018-01-08

Family

ID=47669212

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018000297A MX372754B (es) 2011-08-08 2012-08-08 Metodos y composiciones relacionadas con p62 para el tratamiento y profilaxis del cancer.
MX2014001418A MX353299B (es) 2011-08-08 2012-08-08 Metodos y composiciones relacionadas con p62 para el tratamiento y profilaxis del cancer.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018000297A MX372754B (es) 2011-08-08 2012-08-08 Metodos y composiciones relacionadas con p62 para el tratamiento y profilaxis del cancer.

Country Status (14)

Country Link
US (3) US9717781B2 (es)
EP (1) EP2750694B8 (es)
JP (1) JP6193231B2 (es)
KR (1) KR102001582B1 (es)
CN (1) CN103889440A (es)
AU (1) AU2012294454B2 (es)
BR (1) BR112014002817A2 (es)
CA (1) CA2844283C (es)
CL (1) CL2014000291A1 (es)
EA (1) EA026228B1 (es)
IL (1) IL230770A0 (es)
MX (2) MX372754B (es)
SG (1) SG2014008411A (es)
WO (1) WO2013022991A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10441810B2 (en) * 2007-04-08 2019-10-15 Immunolight, Llc X-ray psoralen activated cancer therapy (X-PACT)
EP2750694B8 (en) * 2011-08-08 2018-11-14 Curelab Oncology, Inc. Methods and compositions relating to p62 for the treatment and prophylaxis of cancer
US20130345143A1 (en) * 2012-01-31 2013-12-26 Rutgers, The State University Of New Jersey MODULATION OF p62 FUNCTION THROUGH THE PB1 DOMAIN
US20160032005A1 (en) * 2013-03-29 2016-02-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceuticals compositions for treating breast cancers
AU2014369861B2 (en) * 2013-12-29 2018-09-13 Curelab Oncology, Inc. Methods and compositions relating to p62/SQSTM1 for the treatment and prevention of inflammation-associated diseases
CN105079780B (zh) * 2014-05-04 2020-07-14 中国医学科学院药物研究所 一种特异结合trb3的多肽在治疗腹主动脉瘤中的应用
WO2016082192A1 (zh) * 2014-11-28 2016-06-02 中国医学科学院药物研究所 与trb3蛋白特异性结合的多肽，其筛选方法、鉴定和用途
CN106063928B (zh) * 2015-04-23 2020-07-14 中国医学科学院药物研究所 一种多肽或其衍生物在治疗高血压性心肌肥厚中的应用
WO2016207730A1 (en) * 2015-06-22 2016-12-29 The University Of Oslo Targeting of vaccine antigen to an intracellular compartment
CA3002394A1 (en) 2015-10-19 2017-04-27 Immunolight, Llc X-ray psoralen activated cancer therapy (x-pact)
WO2018029256A1 (en) 2016-08-09 2018-02-15 Aarhus Universitet Modulation of ifi16 and sting activity
CN106153922B (zh) * 2016-09-14 2018-03-06 深圳大学 一种结肠癌预后预测标志物及其检测方法
US12059413B2 (en) 2016-11-02 2024-08-13 The Research Foundation For The State University Of New York Methods of inhibiting viruses using compositions targeting TSG101-ubiquitin interaction
US20210030870A1 (en) * 2018-02-06 2021-02-04 Stipe Therapeutics Aps Modulation of p62 and sting activity
US20210220437A1 (en) * 2018-08-02 2021-07-22 Curelab Oncology, Inc. Compositions and Methods Relating to p62 for the Treatment and Prophylaxis of Age-Related Macular Degeneration
EP4045150B1 (en) * 2019-10-16 2025-11-26 Enterome S.A. Immunogenic compounds for treatment of adrenal cancer
WO2022129180A1 (en) * 2020-12-15 2022-06-23 Centre National De La Recherche Scientifique Sqstm1 and its use in cancer therapy
CN116917009A (zh) 2021-02-19 2023-10-20 美国迈胜医疗系统有限公司 用于粒子治疗系统的机架
AU2022441199A1 (en) * 2021-09-27 2024-05-16 Curelab Oncology, Inc. Prevention and treatment of diseases by modulating activity of mesenchymal stem cells with p62 (sqstm1)-encoding vector and pharmaceutical formulations containing p62 (sqstm1) proteins
CN114106207B (zh) * 2022-01-24 2022-04-26 诺未科技（北京）有限公司 Ccl5的用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364773A (en) 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
JP3011939B2 (ja) 1987-03-02 2000-02-21 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 組換えミコバクテリア・ワクチン
US5504005A (en) 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine
AU648505B2 (en) 1989-05-19 1994-04-28 Amgen, Inc. Metalloproteinase inhibitor
WO1991013157A1 (en) 1990-02-26 1991-09-05 Commonwealth Scientific And Industrial Research Organisation Shuttle plasmid for escherichia coli and mycobacteria
GB9015888D0 (en) 1990-07-19 1990-09-05 Smithkline Biolog Vectors
AU672359B2 (en) 1991-03-07 1996-10-03 Virogenetics Corporation Genetically engineered vaccine strain
US5610276A (en) 1991-05-17 1997-03-11 Chiron Corporation Polypeptides and antibodies derived from GAP associated protein, p62
AU2185592A (en) 1991-06-06 1993-01-08 Med Immune, Inc. Induction of ctl responses to foreign antigens expressed in mycobacteria
FR2734826B1 (fr) * 1995-06-01 1997-07-04 Rhone Poulenc Rorer Sa Deltap62, ses variants, sequences nucleiques et leurs utilisations
US5962224A (en) * 1995-12-19 1999-10-05 Dana-Farber Cancer Institute Isolated DNA encoding p62 polypeptides and uses therefor
US5990091A (en) 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
AU763183B2 (en) 1998-08-18 2003-07-17 Research Development Foundation Methods to enhance and confine expression of genes
WO2001093897A2 (en) 2000-06-02 2001-12-13 Entremed, Inc. Angiostatin and endostatin binding proteins and methods of use
US20030232399A1 (en) * 2000-06-14 2003-12-18 Robertson John Forsyth Russell Cancer detection methods and reagents
EP1506228B1 (en) * 2002-05-14 2009-01-21 Jaekyoon Shin Role of p62 in aging-related disease
EP1694839A2 (en) * 2003-12-12 2006-08-30 Novo Nordisk A/S Laminin-5 modulators and uses thereof
US8444973B2 (en) * 2005-02-15 2013-05-21 Duke University Anti-CD19 antibodies and uses in B cell disorders
EP2221063A1 (en) * 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
EP2456790A1 (en) * 2009-07-20 2012-05-30 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
WO2011083637A1 (ja) * 2010-01-07 2011-07-14 財団法人東京都医学総合研究所 肝疾患治療薬
EP2750694B8 (en) * 2011-08-08 2018-11-14 Curelab Oncology, Inc. Methods and compositions relating to p62 for the treatment and prophylaxis of cancer

Also Published As

Publication number Publication date
KR102001582B1 (ko) 2019-07-18
AU2012294454A1 (en) 2014-02-13
SG2014008411A (en) 2014-03-28
US20140161824A1 (en) 2014-06-12
MX372754B (es) 2020-06-29
JP6193231B2 (ja) 2017-09-06
CN103889440A (zh) 2014-06-25
EA201490423A1 (ru) 2014-07-30
WO2013022991A3 (en) 2013-04-18
MX2014001418A (es) 2014-09-15
EA026228B1 (ru) 2017-03-31
WO2013022991A2 (en) 2013-02-14
EP2750694B8 (en) 2018-11-14
CL2014000291A1 (es) 2014-08-08
HK1200086A1 (en) 2015-07-31
IL230770A0 (en) 2014-03-31
EP2750694A4 (en) 2015-04-15
CA2844283A1 (en) 2013-02-14
US10716837B2 (en) 2020-07-21
US9717781B2 (en) 2017-08-01
BR112014002817A2 (pt) 2021-09-08
AU2012294454B2 (en) 2017-02-02
US20170043002A1 (en) 2017-02-16
JP2014527053A (ja) 2014-10-09
KR20140083976A (ko) 2014-07-04
US20200338176A1 (en) 2020-10-29
EP2750694A2 (en) 2014-07-09
EP2750694B1 (en) 2018-09-19
CA2844283C (en) 2024-06-04

Similar Documents

Publication Publication Date Title
MX353299B (es) Metodos y composiciones relacionadas con p62 para el tratamiento y profilaxis del cancer.
PH12019502292A1 (en) Methods and compositions for treatment of a genetic condition
MD20150091A2 (ro) Compuşi antivirali
PH12015500525A1 (en) Formulations of enzalutamide
IN2014KN00848A (es)
PH12014502772A1 (en) Substituted tricyclic compounds as fgfr inhibitors
UA111386C2 (uk) Піридопіразини, які мають протиракову активність через інгібування fgfr-кіназ
MX356525B (es) Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia.
IN2014KN02601A (es)
IN2014CN03555A (es)
IN2015DN00372A (es)
IN2015DN01151A (es)
PH12014502032A1 (en) Treatment of brain cancer
MX2015003701A (es) Composiciones para tratamiento.
MX347541B (es) Analogos de acido sialico.
MX363385B (es) Métodos para el tratamiento de enfermedad de células falciformes y otras condiciones inflamatorias.
IN2014DN03010A (es)
IN2014DN08443A (es)
UA117567C2 (uk) Композиція, яка стимулює лактацію, на основі фосфатидилсерину
IN2014DN07989A (es)

Legal Events

Date Code Title Description
FG Grant or registration